Background: Survival data of diffuse adult-type glioma is mostly based on prospective clinical trials or small retrospective cohort studies. Real-world data with large patient cohorts is currently lacking.
Methods: Using the nationwide, population-based Belgian Cancer Registry, all known histological reports of patients diagnosed with an adult-type diffuse glioma in Belgium between 2017 and 2019 were reviewed. The ICD-O-3 morphology codes were matched with the histological diagnosis. The gathered data were transformed into the 2021 World Health Organization classification of CNS tumors using the IDH- and 1p/19q-mutation status.
Results: Between 2017 and 2019, 2233 diffuse adult-type gliomas were diagnosed in Belgium. Full molecular status was available in 67.1% of identified cases. The age-standardized incidence rate of diffuse adult-type glioma in Belgium was estimated at 8.55 per 100 000 person-years and 6.72 per 100 000 person-years for grade 4 lesions. Median overall survival time in IDH-wild-type glioblastoma was 9.3 months, significantly shorter compared to grade 4 IDH-mutant astrocytoma (median survival time: 25.9 months). The 3-year survival probability was 86.0% and 75.7% for grades 2 and 3 IDH-mutated astrocytoma. IDH-wild-type astrocytoma has a worse prognosis with a 3-year survival probability of 31.6% for grade 2 and 5.7% for grade 3 lesions.
Conclusions: This registry-based study presents a large cohort of adult-type diffuse glioma with known molecular status and uses real-world survival data. It adds to the current literature which is mainly based on historical landmark trials and smaller retrospective cohort studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768998 | PMC |
http://dx.doi.org/10.1093/neuonc/noad158 | DOI Listing |
Neurochirurgie
December 2024
Institute of Functional Genomics, Montpellier University, CNRS, INSERM, Montpellier, France; French Brain Tumor DataBase (Recensement national histologique des Tumeurs Primitives du SNC), CHU/ICM Montpellier, Montpellier, France; Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
Background: The recent advent of anti-IDH therapies and changes in the WHO classification of gliomas implies estimating the number of patients who could benefit (or not) from anti-IDH treatment. As published data on the current incidence of different subtypes of IDH-mutant gliomas (based on the latest histomolecular WHO classification) are lacking in many countries. The present analysis aims to review the main factors impacting the incidence of gliomas and lower-grade gliomas and to estimate the incidence and prevalence of IDH-mutant gliomas in France.
View Article and Find Full Text PDFNeurooncol Adv
November 2024
Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Background: Radiologically presumed diffuse lower-grade glioma (dLGG) are typically non or minimal enhancing tumors, with hyperintensity in T2w-images. The aim of this study was to test the clinical usefulness of deep learning (DL) in mutation prediction in patients with radiologically presumed dLGG.
Methods: Three hundred and fourteen patients were retrospectively recruited from 6 neurosurgical departments in Sweden, Norway, France, Austria, and the United States.
Diagnostics (Basel)
November 2024
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Isocitrate dehydrogenase (IDH) and O-methylguanine-DNA methyltransferase (MGMT) genes are critical molecular markers in determining treatment options and predicting the prognosis of adult-type diffuse gliomas. : this study aimed to investigate whether multimodal MRI enables the differentiation of genotypes in adult-type diffuse gliomas. : a total of 116 adult-type diffuse glioma patients (61 males, 51.
View Article and Find Full Text PDFSci Rep
November 2024
Department of Neurosurgery, Zhongnan Hospital of Wuhan University, No.125 Donghu Road, WuChang, Wuhan, 430062, China.
Comprehensive and non-invasive preoperative molecular diagnosis is important for prognostic and therapy decision-making in adult-type diffuse gliomas. We employed a deep learning method for automatic segmentation of brain gliomas directly from conventional magnetic resonance imaging (MRI) scans of the tumor core and peritumoral edema regions based on available glioma MRI data provided in the BraTS2021. Three-dimensional volumes of interest were segmented from 424 cases of glioma imaging data retrospectively obtained from two medical centers using the segmentation method and radiomic features were extracted.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
January 2025
Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia; The Brain Cancer Group, Sydney, New South Wales, Australia; Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia; Central Coast Cancer Centre, Gosford Hospital, Gosford, New South Wales, Australia.
Purpose: To summarise existing literature examining amino acid positron emission tomography (AA-PET) for radiotherapy target volume delineation in patients with gliomas.
Methods: Systematic search of MEDLINE and EMBASE databases.
Results: Twenty studies met inclusion criteria.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!